2. Signaling Pathways
  3. Neuronal Signaling
  4. Beta-secretase

Beta-secretase

BACE; β-Secretase

Beta-secretase

Related Products

PDF 0.56 MB

Beta-secretase (BACE) is a transmembrane aspartic proteinase responsible for cleaving the amyloid precursor protein (APP) to generate the soluble ectodomain sAPPbeta and its C-terminal fragment CTFbeta. BACE is a major target of Alzheimer's disease (AD) therapeutics. There are two forms of the enzyme: BACE1 and BACE2.

Deposition of amyloid-β protein (Aβ) to form neuritic plaques is the characteristic neuropathology of Alzheimer's disease (AD). Aβ is generated from APP by β- and γ-secretase cleavages. BACE1 is the β-secretase and its inhibition induces severe side effects, whereas its homolog BACE2 normally suppresses Aβ by cleaving APP/Aβ at the θ-site (Phe20) within the Aβ domain.

Beta-secretase Isoform Specific Products:

Beta-secretase Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100740B
    Lanabecestat camsylate
    		Inhibitor
    Lanabecestat camsylate is a potent, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM. Lanabecestat camsylate is used for the research of Alzheimer's disease.
    Lanabecestat camsylate
  • HY-18112
    AZ-4217
    		Inhibitor
    AZ-4217 is an inhibitor for β-site amyloid precursor protein cleavage enzyme 1 (BACE1), with IC50 of 160 pM in human SH-SY5Y cells. AZ-4217 reduces amyloid deposition in Tg2576 mouse models, and is used for Alzheimer’s Disease research.
    AZ-4217
  • HY-16759B
    Verubecestat tosylate
    		Inhibitor
    Verubecestat tosylate is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat tosylate effectively reduces Aβ40 and has the potential for Alzheimer's Disease.
    Verubecestat tosylate
  • HY-100740R
    Lanabecestat (Standard)
    		Inhibitor
    Lanabecestat (Standard) is the analytical standard of Lanabecestat. This product is intended for research and analytical applications. Lanabecestat (AZD3293) is a potent, orally active and blood-brain barrier penetrating BACE1 inhibitor with a Ki of 0.4 nM. Lanabecestat is used for the research of Alzheimer's disease.
    Lanabecestat (Standard)
  • HY-114703R
    Eslicarbazepine (Standard)
    		Inhibitor
    Eslicarbazepine (Standard) is the analytical standard of Eslicarbazepine. This product is intended for research and analytical applications. Eslicarbazepine is an oral anticonvulsant indicated for the adjunctive treatment of partial seizures.
    Eslicarbazepine (Standard)
  • HY-P2714
    SEVNLDAEFR
    SEVNLDAEFR is a substrate for BACE1.
    SEVNLDAEFR
  • HY-114234A
    TAK-070 Free base
    		Inhibitor
    TAK-070 Free base is a noncompetitive and orally active BACE1 inhibitor (IC50: 3.15 μM). TAK-070 Free base can be used for research of Alzheimer’s disease (AD). TAK-070 Free base inhibits brain levels of soluble Aβ, and improves cognitive impairments in AD model.
    TAK-070 Free base
  • HY-160037
    SEW06622
    		Inhibitor
    SEW06622 is a BACE-1 inhibitor with an IC50 value of 6.3 μM and can be used in Alzheimer's disease research.
    SEW06622
  • HY-N2215R
    Aloeresin D (Standard)
    		Inhibitor
    Aloeresin D (Standard) is the analytical standard of Aloeresin D. This product is intended for research and analytical applications. Aloeresin D is a chromone glycoside isolated from Aloe vera, inhibits β-Secretase (BACE1) activity, with an IC50 of 39 μM.
    Aloeresin D (Standard)
  • HY-138013
    PF-06663195
    		Inhibitor
    PF-06663195 is a β-secretase (BACE1) inhibitor, with BACE1 CFA and BACE1 WCA IC50 values of 53 and 15 nM, respectively. PF-06663195 can be used for Alzheimer's disease research.
    PF-06663195
  • HY-16759R
    Verubecestat (Standard)
    		Inhibitor
    Verubecestat (Standard) is the analytical standard of Verubecestat. This product is intended for research and analytical applications. Verubecestat (MK-8931) is an orally active, high-affinity BACE1 and BACE2 inhibitor with Ki values of 2.2 nM and 0.38 nM. Verubecestat effectively reduces Aβ40 and has the potential for Alzheimer's Disease.
    Verubecestat (Standard)
  • HY-U00287
    BACE-IN-1
    		Inhibitor
    BACE-IN-1 (Compound 13) is a substituted lmidazo[1 ,2-a]pyridine derivative which can inhibit β-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment of diseases in which BACE is involved, such as Alzheimer's disease.
    BACE-IN-1
Cat. No. Product Name / Synonyms Application Reactivity
Beta-secretase Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.